- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic rhinosinusitis with nasal polyps
- Meeting Date: November 2021
- Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 1439KB)
- Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 142KB)
Mepolizumab – November 2021
Mepolizumab: Injection 100 mg in 1 mL single dose pre-filled pen; Nucala®
Last updated
18 March 2022